Bacterial Pneumonia Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Bacterial Pneumonia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP)), By Treatments (Vaccines, Drugs), By Route of Administration (Oral, Subcutaneous, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Bacterial Pneumonia Market is projected to expand significantly, rising from USD 2.64 Billion in 2025 to USD 4.02 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 7.26%. This market addresses bacterial pneumonia, a serious lower respiratory infection often caused by Streptococcus pneumoniae, leading to inflammation and fluid in the lung's air sacs. Key growth catalysts include the increasing global elderly population, who are more susceptible to infections due to weakened immune systems, and the rising incidence of chronic respiratory conditions like COPD.Data from the American Lung Association in 2025 indicated that adults aged 65 and above were over ten times more likely to require hospitalization for pneumococcal pneumonia compared to those aged 18 to 49, highlighting an urgent need for effective treatments in older populations. Furthermore, strong government policies supporting national immunization programs are fundamental to maintaining demand for preventive solutions. However, the market faces a substantial challenge from the swift rise of antimicrobial resistance, as multidrug-resistant bacteria diminish the effectiveness of conventional antibiotics, complicating patient care and mandating substantial investment in new drug development, thereby hindering overall market growth.
Market Driver
A key driver for the Global Bacterial Pneumonia Market is the intensification of worldwide immunization and vaccination campaigns, significantly boosted by the development of next-generation conjugate vaccines offering broader protection against various serotypes. Regulatory agencies are fast-tracking approvals for these advanced biological products to close existing gaps in both adult and pediatric defense against aggressive bacterial strains. For example, Merck reported in June 2024 that the U.S. FDA approved a new 21-valent conjugate vaccine, CAPVAXIVE, specifically targeting serotypes responsible for roughly 84% of invasive pneumococcal disease in individuals aged 50 and older.This commitment to improved preventive care is also evident in widespread international deployment, with the World Health Organization's July 2024 report on Immunization Coverage indicating that global coverage for the third dose of pneumococcal conjugate vaccine reached an estimated 65% by the end of 2023, reflecting ongoing efforts to lessen the disease burden through extensive vaccination. Simultaneously, the increasing global prevalence of bacterial pneumonia, particularly with the post-pandemic resurgence of respiratory pathogens, is fueling demand for both treatment and diagnostic tools. Healthcare systems are experiencing a significant surge in patient numbers, especially among susceptible younger groups, necessitating greater supplies of antibiotics and hospital infrastructure, which in turn drives market expansion and helps mitigate the challenges presented by antimicrobial resistance.
Market Challenge
Antimicrobial resistance poses a direct impediment to the growth of the Global Bacterial Pneumonia Market, significantly undermining the clinical effectiveness and commercial future of existing pharmaceutical treatments. As bacterial pathogens increasingly develop resistance to standard first-line antibiotics, the market is confronted with a severe efficacy challenge, rendering many inexpensive, high-volume generic drugs ineffective. This loss of effectiveness creates considerable market volatility, compelling healthcare providers to forsake established treatment guidelines in favor of alternative therapies, which are frequently less available or carry greater toxicity risks.Consequently, the market becomes fragmented, with the frequent failure of standard drugs discouraging consistent prescription volumes and thereby impeding the sector's overall expansion. The severity of this challenge is evident in recent surveillance data concerning major respiratory pathogens; for instance, the World Health Organization reported in 2025 that global resistance to third-generation cephalosporins in Klebsiella pneumoniae, a bacterium commonly linked to severe pneumonia, surpassed 55%. Such high resistance levels dramatically shrink the potential market for traditional antibiotic categories, forcing the industry to reallocate resources towards risky research into new compounds instead of enhancing existing treatments, thus forming a bottleneck that obstructs the steady advancement of the Global Bacterial Pneumonia Market.
Market Trends
The integration of Artificial Intelligence (AI) into pneumonia imaging and detection is significantly advancing diagnostic accuracy, effectively addressing the inherent human challenges in interpreting intricate radiographs. Sophisticated algorithms can now discern nuanced patterns indicative of pathogen-induced changes, enabling quicker and more precise therapeutic interventions. For instance, a New Atlas article from January 2025 highlighted a new AI model achieving 96.57% diagnostic accuracy, considerably surpassing conventional techniques in distinguishing pneumonia from other respiratory ailments.This technological validation is accelerating the adoption of AI tools into clinical practices, where they function as dependable second readers, thereby minimizing diagnostic inaccuracies and improving resource allocation in busy healthcare environments. Simultaneously, the growing adoption of syndromic panel testing for respiratory pathogens is fundamentally transforming clinical management by facilitating the swift differentiation of co-occurring viral and bacterial infections. This trend involves moving from single-pathogen tests to multiplexed molecular assays, which streamline patient assessment during periods of high respiratory illness. As reported by Cepheid in January 2025, the company obtained FDA approval for a rapid molecular test that can simultaneously identify four different viral targets, including SARS-CoV-2 and influenza, from a single sample. The use of these comprehensive panels shortens diagnosis times, reduces inappropriate antibiotic prescriptions, and refines isolation procedures in healthcare settings.
Key Market Players
* Innoviva Inc
* Pfizer Inc.
* Merck & Co., Inc.
* Melinta Therapeutics LLC
* Evopoint Biosciences
* Aridis Pharmaceuticals Inc.
* Cumberland Pharmaceuticals Inc.
* Eagle Pharmaceuticals, Inc.
* Clarametyx Biosciences
* Basilea Pharmaceutica Ltd
Report Scope
In this report, the Global Bacterial Pneumonia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Bacterial Pneumonia Market, By Type
* Community-Acquired Pneumonia (CAP)
* Hospital-Acquired Pneumonia (HAP)
# Bacterial Pneumonia Market, By Treatments
* Vaccines
* Drugs
# Bacterial Pneumonia Market, By Route of Administration
* Oral
* Subcutaneous
* Other
# Bacterial Pneumonia Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Bacterial Pneumonia Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Pneumonia Market.
Available Customizations:
Global Bacterial Pneumonia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bacterial Pneumonia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP))
5.2.2. By Treatments (Vaccines, Drugs)
5.2.3. By Route of Administration (Oral, Subcutaneous, Other)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Bacterial Pneumonia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Treatments
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Bacterial Pneumonia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatments
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Bacterial Pneumonia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatments
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Bacterial Pneumonia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatments
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
7. Europe Bacterial Pneumonia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Treatments
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bacterial Pneumonia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatments
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. France Bacterial Pneumonia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatments
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Bacterial Pneumonia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatments
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Bacterial Pneumonia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Treatments
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Bacterial Pneumonia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Treatments
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Bacterial Pneumonia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatments
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Bacterial Pneumonia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatments
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. India Bacterial Pneumonia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatments
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Bacterial Pneumonia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatments
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Bacterial Pneumonia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Treatments
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Bacterial Pneumonia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Treatments
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Bacterial Pneumonia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatments
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Bacterial Pneumonia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatments
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Bacterial Pneumonia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatments
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Bacterial Pneumonia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Treatments
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. South America Bacterial Pneumonia Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Treatments
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Bacterial Pneumonia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Treatments
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Bacterial Pneumonia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Treatments
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Bacterial Pneumonia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Treatments
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Bacterial Pneumonia Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Innoviva Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Merck & Co., Inc.
15.4. Melinta Therapeutics LLC
15.5. Evopoint Biosciences
15.6. Aridis Pharmaceuticals Inc.
15.7. Cumberland Pharmaceuticals Inc.
15.8. Eagle Pharmaceuticals, Inc.
15.9. Clarametyx Biosciences
15.10. Basilea Pharmaceutica Ltd
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們